Analytical Data
-
Gene name
EVER1
- Application
-
Alternative Names
TMC6; EVER1; EVIN1Transmembrane channel-like protein 6; Epidermodysplasia verruciformis protein 1; Protein LAK-4
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q7Z403
-
Expression Region
1-444aa
-
AA Sequence
MAHSFGESYRVGSTSGIHAITVFCSWDYKVTQKRASRLQQDNIRTRLKELLAEWQLRHSPRSVCGRLRQAAVLGLVWLLCLGTALGCAVAVHVFSEFMIQSPEAAGQEAVLLVLPLVVGLLNLGAPYLCRVLAALEPHDSPVLEVYVAICRNLILKLAILGTLCYHWLGRRVGVLQGQCWEDFVGQELYRFLVMDFVLMLLDTLFGELVWRIISEKKLKRRRKPEFDIARNVLELIYGQTLTWLGVLFSPLLPAVQIIKLLLVFYVKKTSLLANCQAPRRPWLASHMSTVFLTLLCFPAFLGAAVFLCYAVWQVKPSSTCGPFRTLDTMYEAGRVWVRHLEAAGPRVSWLPWVHRYLMENTFFVFLVSALLLAVIYLNIQVVRGQRKVICLLKEQISNEGEDKIFLINKLHSIYERKEREERSRVGTTEEAAAPPALLTDEQDA
-
Molecular Weight
74.58 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
EVER1, also known as E3 ubiquitin-protein ligase TRIM36, has garnered significant interest in recent years due to its role in the immune response and skin biology. Researchers have identified EVER1 as a critical player in the host defense against viral infections, particularly in the context of human papillomavirus (HPV). Expression of EVER1 is closely linked to the regulation of immune responses, where it acts to modulate the activity of various signaling pathways, particularly those involved in the antiviral response. Furthermore, mutations in the EVER1 gene have been associated with increased susceptibility to HPV-related skin lesions, underscoring its importance in maintaining cutaneous health. A deeper understanding of EVER1's molecular function and its interactions with other proteins involved in innate immunity may shed light on potential therapeutic strategies for viral infections and skin disorders. As research progresses, the potential for EVER1 as a biomarker for HPV risk assessment and its implications in vaccine development also emerge as promising areas of investigation. Through advanced techniques such as recombinant protein expression and functional assays, scientists aim to elucidate the full spectrum of EVER1's biological roles, paving the way for innovative approaches in treating related diseases.
